A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) is a global biotechnology platform company based in Jupiter, Florida with operations in the United States and a satellite office in the Netherlands, and it utilizes several third-party consultants and contract research organizations to carry out the Company’s activities. Over the past two plus decades, the Company developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins, and previously licensed this technology to third parties, such as Abengoa Bioenergy SA, BASF SE, Codexis, Inc. and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the Thermothelomyces heterothallica (formerly known as Myceliophthora thermophila) fungus, which the Company named C1.
| Metric | TTM | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | 3.3M | 3.5M | - | - | - | - |
| Net Income | -7.3M | -5.8M | -6.8M | -9.7M | -13M | -9.3M |
| EPS | $-0.22 | $-0.20 | $-0.24 | $-0.34 | $-0.47 | $-0.34 |
| Free Cash Flow | 0 | -4.0M | -6.7M | -8.1M | -11M | -6.6M |
| ROIC | -48.6% | -46.9% | -79.1% | -87.8% | -71.1% | -32.8% |
| Gross Margin | - | 65.8% | - | - | - | - |
| Debt/Equity | 1.13 | 1.62 | 0.02 | 0.24 | 0.16 | 0.06 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -7.2M | -5.9M | -8.2M | -10M | -15M | -10M |
| Operating Margin | -215.0% | -168.8% | - | - | - | - |
| ROE | -281.8% | -139.2% | -115.6% | -87.8% | -71.1% | -32.8% |
| Shares Outstanding | 36M | 29M | 28M | 29M | 28M | 27M |
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | |||
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 3.5M | 3.3M |
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 65.8% | N/A |
| R&D | 1.8M | 2.1M | 3.1M | 3.9M | 8.4M | 4.5M | 3.3M | 2.0M | 2.2M |
| SG&A | 5.0M | 4.5M | 5.5M | 6.1M | 6.7M | 6.4M | 5.8M | 6.1M | 6.0M |
| EBIT | -7.1M | -7.6M | -9.3M | -10M | -15M | -10M | -8.2M | -5.9M | -7.2M |
| Op. Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -168.8% | -215.0% |
| Net Income | -2.1M | -5.7M | -8.3M | -9.3M | -13M | -9.7M | -6.8M | -5.8M | -7.3M |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -166.2% | -219.9% |
| Non-Recurring | 0 | 0 | 0 | 0 | 0 | 0 | 1.0M | 63K | 2K |
| Returns on Capital | |||||||||
| ROIC | -14.0% | -17.5% | -24.8% | -32.8% | -71.1% | -87.8% | -79.1% | -46.9% | -48.6% |
| ROE | N/A | N/A | N/A | -32.8% | -71.1% | -87.8% | -115.6% | -139.2% | -281.8% |
| ROA | -4.2% | -12.1% | -20.6% | -31.0% | -61.4% | -71.0% | -82.7% | -64.0% | -63.0% |
| Cash Flow | |||||||||
| Op. Cash Flow | -1.7M | -4.4M | -5.8M | -6.6M | -11M | -8.1M | -6.7M | -4.0M | -4.6M |
| Free Cash Flow | -1.7M | -4.4M | -5.8M | -6.6M | -11M | -8.1M | -6.7M | -4.0M | 0 |
| Owner Earnings | -2.3M | -4.9M | -7.0M | -8.2M | -13M | -10.0M | -8.0M | -5.1M | -5.6M |
| CapEx | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Maint. CapEx | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Growth CapEx | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0 |
| D&A | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CapEx/OCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Capital Allocation | |||||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 6.2M | 2.3M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | 14.8% | 4.5% | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Stock-Based Comp | 643K | 467K | 1.2M | 1.7M | 1.8M | 1.9M | 1.2M | 1.1M | 1.0M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Balance Sheet | |||||||||
| Net Debt | N/A | N/A | N/A | N/A | N/A | N/A | -7.1M | -5.3M | -6.0M |
| Cash & Equiv. | 5.8M | 2.4M | 4.8M | 21M | 16M | 5.8M | 6.5M | 6.5M | 8.9M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | 0 | 3.9M | 3.0M |
| Debt/Equity | N/A | N/A | N/A | 0.06 | 0.16 | 0.24 | 0.02 | 1.62 | 1.13 |
| Interest Coverage | N/A | N/A | N/A | -22.4 | -284.8 | -56.3 | N/A | -20.5 | -20.5 |
| Equity | N/A | N/A | N/A | 28M | 18M | 11M | 5.9M | 2.5M | 2.6M |
| Total Assets | 51M | 43M | 37M | 30M | 21M | 14M | 8.2M | 9.9M | 12M |
| Total Liabilities | N/A | N/A | N/A | 1.6M | 2.9M | 2.6M | 2.3M | 7.5M | 9.1M |
| Intangibles | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Retained Earnings | -27M | -33M | -41M | -51M | -64M | -73M | -80M | -86M | -92M |
| Working Capital | 49M | 42M | 34M | 28M | 18M | 11M | 5.8M | 7.4M | 7.5M |
| Current Assets | 50M | 43M | 36M | 30M | 21M | 13M | 8.1M | 9.8M | 12M |
| Current Liabilities | 769K | 850K | 1.6M | 1.6M | 2.6M | 2.4M | 2.3M | 2.4M | 4.1M |
| Per Share Data | |||||||||
| EPS | -0.07 | -0.21 | -0.31 | -0.34 | -0.47 | -0.34 | -0.24 | -0.20 | -0.22 |
| Owner EPS | -0.08 | -0.18 | -0.26 | -0.30 | -0.47 | -0.35 | -0.28 | -0.18 | -0.16 |
| Book Value | N/A | N/A | N/A | 1.04 | 0.66 | 0.39 | 0.21 | 0.09 | 0.07 |
| Cash Flow/Share | -0.06 | -0.16 | -0.22 | -0.24 | -0.41 | -0.28 | -0.24 | -0.14 | -0.20 |
| Dividends/Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 30.5M | 27.1M | 26.8M | 27.4M | 27.8M | 28.6M | 28.3M | 29.0M | 36.2M |
| Valuation | |||||||||
| P/E Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -4.0 |
| P/FCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Book | N/A | N/A | N/A | 5.2 | 6.6 | 3.2 | 8.0 | 23.9 | 12.1 |
| Price/Sales | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 12.7 | 9.4 |
| FCF Yield | -4.0% | -8.6% | -4.1% | -4.4% | -9.3% | -22.9% | -14.2% | -6.7% | N/A |
| Market Cap | 42M | 51M | 142M | 148M | 121M | 35M | 47M | 59M | 31M |
| Avg. Price | 1.43 | 1.59 | 4.68 | 6.71 | 4.67 | 2.68 | 1.76 | 1.48 | 0.87 |
| Year-End Price | 1.38 | 1.90 | 5.28 | 5.40 | 4.20 | 1.22 | 1.57 | 1.96 | 0.87 |
DYADIC INTERNATIONAL INC passes 1 of 9 quality checks, indicating weak fundamentals.
The company's 5-year average gross margin is 65.8%.
DYADIC INTERNATIONAL INC (DYAI) has a 5-year average return on invested capital (ROIC) of -63.5%. This is below average and may indicate limited pricing power.
DYADIC INTERNATIONAL INC (DYAI) has a market capitalization of $31M. It is classified as a small-cap stock.
DYADIC INTERNATIONAL INC (DYAI) does not currently pay a regular dividend.
DYADIC INTERNATIONAL INC (DYAI) operates in the Biological Products, (No Diagnostic Substances) industry, within the Healthcare sector.
DYADIC INTERNATIONAL INC (DYAI) reported annual revenue of $3 million in its most recent fiscal year, based on SEC EDGAR filings.
DYADIC INTERNATIONAL INC (DYAI) has a net profit margin of -166.2%. The company is currently unprofitable.
DYADIC INTERNATIONAL INC (DYAI) generated $-4 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
DYADIC INTERNATIONAL INC (DYAI) has a debt-to-equity ratio of 1.62. This indicates higher leverage, which may increase financial risk.
DYADIC INTERNATIONAL INC (DYAI) reported earnings per share (EPS) of $-0.20 in its most recent fiscal year.
DYADIC INTERNATIONAL INC (DYAI) has a return on equity (ROE) of -139.2%. A negative ROE may indicate losses or negative equity.
DYADIC INTERNATIONAL INC (DYAI) has a 5-year average gross margin of 65.8%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 8 years of financial data for DYADIC INTERNATIONAL INC (DYAI), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
DYADIC INTERNATIONAL INC (DYAI) has a book value per share of $0.09, based on its most recent annual SEC filing.